Treatment to benefit African infants at risk of endemic fever

Key points
- Thousands of pre-school children in Africa could benefit from access to treatment for an endemic disease, after tests showed infants to be at high risk of infection.
- Although a few patients may have minor skin irritation when the cercariae enter the skin, most people do not develop symptoms until the eggs develop (about one to two months after initial skin penetration).
- Researchers tested hundreds of children aged between one and five in countries in sub-Saharan Africa where snail fever – also known as bilharzia or schistosomiasis – is endemic.
- Scientists showed that in fact, infection rates are high among pre-school children.
Thousands of pre-school children in Africa could benefit from access to treatment for an endemic disease, after tests showed infants to be at high risk of infection.
Researchers tested hundreds of children aged between one and five in countries in sub-Saharan Africa where snail fever – also known as bilharzia or schistosomiasis – is endemic. Currently, infants are not regularly tested for infection as they are perceived to be at low risk of exposure to the water-borne disease and not to suffer severely from its ill-effects.
Scientists showed that in fact, infection rates are high among pre-school children. This may be because they often accompany their mothers to rivers and wells. Symptoms of the disease – which can include impaired memory and thought as well as damage to internal organs and stunted growth – are not always obvious.
The study found that a common snail fever drug, known as praziquantel, which is regularly given to older children and adults, can safely cure the infection in infants. The treatment is cheap and effective, curing infection and stopping progress of disease in a single dose.
Researchers from the University of Edinburgh carried out studies in Zimbabwe and their results were combined with work by other teams in Mali, Sudan, Egypt, Niger and Uganda. In a recent World Health Organisation report, the teams recommended that infants be included in treatment programmes, and their work is informing public health policy.
Schistosomiasis, also known as bilharzia, is a disease caused by parasitic worms. Although the worms that cause schistosomiasis are not found in the United States, more than 200 million people are infected worldwide. In terms of impact this disease is second only to malaria as the most devastating parasitic disease. Schistosomiasis is considered one of the Neglected Tropical Diseases (NTDs).
The parasites that cause schistosomiasis live in certain types of freshwater snails. The infectious form of the parasite, known as cercariae, emerge from the snail, hence contaminating water. You can become infected when your skin comes in contact with contaminated freshwater. Most human infections are caused by Schistosoma mansoni, S. haematobium, or S. japonicum.
According to the WHO, snail fever affects 230 million people each year, most of whom are African. Some 33.5 million people were treated for the disease in 2010. Children are especially vulnerable because they make frequent contact with infected water.
Dr Francisca Mutapi, of the University of Edinburgh's School of Biological Sciences, who took part in the study, said: "Snail fever is a widespread disease of major health consequence in young children. Our study shows that infants are especially vulnerable to infection and should be included in public health treatment programmes."
What are the symptoms and signs of schistosomiasis?
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
NewsAntibody therapy opens door to potential new treatment for HIV
The development of antiretroviral therapy , a combination of drugs that slows the replication of HIV in the body , has transformed the treatment of this infection. What was once a certain death sentence is now a chronic…
8 May 2016
NewsEnhanced treatment for hepatitis C could cut prevalence by 80 percent
Novel antiviral therapies for hepatitis C could reduce the prevalence of the blood-borne infection by more than 80%, according to an analysis by Yale researchers. The finding raises the possibility of greatly reducing,…
2 December 2015
NewsHIV discovery - biomarkers predict virus return when treatment is stopped
Scientists are now better able to predict how quickly the HIV virus will return after individuals stop treatment following a discovery by researchers at UNSW Australia and the University of Oxford. The significant…



